人ProIGF-I EA(92 - 105)抗血清是通過用衍生自與白喉類毒素連接的人ProIGF-I EA的E結(jié)構(gòu)域的15個氨基酸的肽免疫兔來制備的。 該肽位于153個氨基酸的ProIGF-I EA的C末端,該ProIGF-I EA來源于人igf-1基因的可變剪接。 抗血清識別ProIGF-I EA,但不識別ProIGF-I EB、ProIGF-I EC、成熟IGF-I或IGF-II。 序列分析表明,由于igf-1基因的選擇性剪接,它可能在包括非人靈長類、兔、豚鼠、狗、馬、綿羊和山羊在內(nèi)的許多其它物種中識別ProIGF-1 EA相關(guān)蛋白,但在嚙齒類中不識別。 Human ProIGF-I EA (92-105) antiserum was prepared by immunising rabbits with a 15 amino acid peptide derived from the E domain of human ProIGF-I EA linked to diphtheria toxoid. The peptide is located at the C terminus of the 153 amino acid ProIGF-I EA derived from alternative splicing of the human igf-1 gene. The antiserum recognises ProIGF-I EA but not ProIGF-I EB, ProIGF-I EC, mature IGF-I or IGF-II. Sequence analysis suggest it is likely to recognise ProIGF-I EA related proteins in a range of other species including non-human primates, rabbit, guinea-pig, dog, horse, sheep and goat but not rodents, due to alternative splicing of the igf-1 gene.
GroPep Bioreagents公司總部位于澳大利亞,成立于1990年,致力于向廣大科研院所、生物技術(shù)及制藥公司開發(fā)、生產(chǎn)和銷售細(xì)胞培養(yǎng)級的活性生長因子(主要集中在胰島素樣生長因子(IGF)領(lǐng)域)、抗體及相關(guān)蛋白試劑,現(xiàn)有產(chǎn)品超過100多個,同時在世界范圍內(nèi)均設(shè)有分銷商。公司在分子生物領(lǐng)域、發(fā)酵學(xué)及重組蛋白和單抗制備方面具有豐富的經(jīng)驗,在制造工藝方面,擁有大量專利技術(shù),GroPep目前已通過AS/NZS ISO 9001:2016質(zhì)量管理體系認(rèn)證。